GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…
Biotechnology
CH, Plan-les-Ouates [HQ]
GNRO.PA/Financial Reporting
Income Statements
11 Sheets · Starting from 2013In Million EUR. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | 7.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
EPS
|
-0.29 | 0.15 | -0.37 | -1.02 | -0.40 | -0.57 | -0.65 | -0.45 | -0.32 | -0.51 | -0.59 | |
| Diluted in mil. | -0.29 | 0.15 | -0.37 | -1.02 | -0.40 | -0.57 | -0.65 | -0.45 | -0.32 | -0.51 | -0.59 | |
|
Profit
|
- - | 7.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Gross Margin | 100.00 | 100.00 | -1,152.31 | -628.35 | -384.35 | -850.01 | - - | - - | - - | - - | - - | |
| Pre Tax | -3.00 | 2.00 | - - | - - | - - | - - | -10.00 | -9.00 | -7.00 | -13.00 | -15.00 | |
| Profit Margin | -16,684.36 | 30.47 | -175.78 | -238.24 | -39.05 | -111.59 | - - | - - | - - | - - | - - | |
| ETR | 0.61 | 20.20 | -0.53 | -0.04 | 23,281.71 | 23,030.09 | 8.80 | 5.82 | 12.87 | 9.73 | 3.60 | |
| Net | -3.00 | 1.00 | - - | - - | - - | - - | -9.00 | -8.00 | -6.00 | -12.00 | -14.00 | |
| Profit Margin | -16,581.99 | 24.32 | -176.71 | -238.33 | -39.05 | -111.59 | - - | - - | - - | - - | - - | |
| EBITDA | -3.00 | 2.00 | - - | - - | - - | - - | -9.00 | -7.00 | -7.00 | -12.00 | -15.00 | |
| EBITDA Margin | -15,839.81 | 31.07 | -169.09 | -206.13 | -38.00 | -107.64 | - - | - - | - - | - - | - - | |
| Operating Income | -3.00 | 2.00 | - - | - - | - - | - - | -9.00 | -8.00 | -7.00 | -13.00 | -15.00 | |
| Operating Margin | -15,882.46 | 30.13 | -170.23 | -206.77 | -38.40 | -108.38 | - - | - - | - - | - - | - - | |
| Interest Income | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Loss | -3.00 | -5.00 | - - | - - | - - | - - | -9.00 | -8.00 | -7.00 | -13.00 | -15.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Operating Expenses
|
-3.00 | -5.00 | - - | - - | - - | - - | -9.00 | -7.00 | -7.00 | -12.00 | -15.00 | |
| R&D | -2.00 | -3.00 | - - | - - | - - | - - | -5.00 | -4.00 | -4.00 | -9.00 | -12.00 | |
| G&A | - - | -1.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| SG&A | - - | -1.00 | - - | - - | - - | - - | -3.00 | -3.00 | -2.00 | -3.00 | -2.00 | |
| S&M | - - | - - | - - | - - | - - | - - | -3.00 | -3.00 | -2.00 | -3.00 | - - | |
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Interest Expenses | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Expenses | - - | - - | - - | - - | - - | - - | - - | -1.00 | - - | - - | - - | |
|
WA Shares Outstanding
|
12.00 | 12.00 | - - | - - | - - | - - | 14.00 | 19.00 | 21.00 | 23.00 | 24.00 | |
| Diluted | 12.00 | 12.00 | - - | - - | - - | - - | 14.00 | 19.00 | 21.00 | 23.00 | 24.00 |